WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year
SHANGHAI, Oct. 10, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced it has received the esteemed AAA ESG rating from Morgan Stanley Capital International (MSCI) for the third consecutive year. This top-tier rating by MSCI, a premier global data provider of ESG ratings and research, places WuXi Biologics among an...
Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)
EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR) Celltrion plans to enter the U.S. ophthalmology market to meet diverse needs of patients suffering from various eye conditions INCHEON,...
Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer’s Disease Research
New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development. FREMONT, Calif., Oct. 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the launch of the NULISAqpcr™ BD-pTau217 Assay— a transformative leap in blood-based quantification of brain-derived phosphorylated tau 217...
Amcor Appoints Stephen R. Scherger as Executive Vice President and Chief Financial Officer
Michael Casamento to return home to Australia to be closer to his family on a full-time basis; Will leave the Company as a result, remaining in an advisory role until June 30, 2026 to support transition Company reaffirms Fiscal 2026 and first quarter Fiscal 2026 outlook ZURICH, Oct. 10, 2025 /PRNewswire/ -- Amcor (NYSE: AMCR, ASX: AMC), a global...
POMDOCTOR LIMITED Announces Closing of Initial Public Offering
GUANGZHOU, China, Oct. 10, 2025 /PRNewswire/ -- POMDOCTOR LIMITED (Nasdaq: POM) (the "Company" or "POMDOCTOR"), a leading online medical services platform for chronic diseases in China, today announced the closing of its initial public offering (the "Offering") of 5,000,004 American Depositary Shares ("ADSs") at a public offering price of US$4.00 per ADS. Six ADSs represent one Class A ordinary...
Lifespan-Backed Algen Biotechnologies Partners with AstraZeneca to Advance AI Drug Discovery
NORWALK, Conn., Oct. 9, 2025 /PRNewswire/ -- Lifespan Vision Ventures congratulates its portfolio company, Algen Biotechnologies, on the announcement of its multi-target research collaboration with AstraZeneca to advance AI-powered drug discovery in immunology. The partnership will combine Algen's cutting-edge functional genomics and machine learning platform with AstraZeneca's deep scientific expertise and global...
Kimberly-Clark Launches Enhanced Global Partnerships to Advance Essential Care for 24 Million Women and Girls
DALLAS, Oct. 9, 2025 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ: KMB) is deepening its commitment to advancing essential care for women and girls through four enhanced strategic, charitable partnerships. Through new programs with Baby2Baby, Plan International, Project HOPE, and UNICEF, Kimberly-Clark aims to expand access to life-changing care in Brazil, Peru, China, India,...
LuX-Valve Plus Approved for Hong Kong-Macao Medicine and Equipment Connect
BEIJING, Oct. 9, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company with comprehensive structural heart disease interventional solutions, recently announced that LuX-Valve Plus transjugular tricuspid valve replacement system, the product of its subsidiary Jenscare Scientific (Netherlands) B.V., has been officially approved to be included in the Medical Device...
Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission
The phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EFS primary endpoint, supporting an early New Drug Application (NDA) submission World-first regimen in gastric cancer that replaces adjuvant chemotherapy with mono-immunotherapy in the perioperative setting The ASTRUM-006 study demonstrated a significant improvement in event-free survival (EFS) and achieved a more than threefold higher pathological...
Field Medical First-in-Human 6-Month Data Selected for Late-Breaking Clinical Trial at VT Symposium 2025
Three sessions feature new outcomes, a live case, and preclinical research with the FieldForce™ Ablation System. CARDIFF-BY-THE-SEA, Calif., and PHILADELPHIA, Oct. 9, 2025 /PRNewswire/ -- Field Medical, Inc., a leader in pulsed field ablation (PFA) technology for ventricular tachycardia (VT), today announced its participation at the 20th Annual International Symposium on Ventricular...
